CHICAGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- "" is the title of a new report from Data Bridge Market Research. Key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive environment are all dissected in detail in the research. This market report provides an orderly estimation of the key challenges in terms of sales, export/import, or revenue that any business may have to face in the coming years. While exploring the market definition, this report precisely researches market driving factors and market restraints. The medication-Assisted Treatment (MAT) market research report also studies the trends in consumer and supply chain dynamics which enables building up production strategies for the Medication-Assisted Treatment (MAT) industry. Moreover, very loyal sources such as journals, newspapers, company websites, and annual reports of the companies have been referred to collect the data which can be relied upon confidently.
The global medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted (MAT) treatment market will grow at a CAGR of 9.4% during the forecast period of 2022 to 2029.
Gain Access to a Sample PDF of the Medication-Assisted Treatment (MAT) Market @
involves the use of medications, combined with counselling and behavioural therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and grow in pregnancy outcomes among women.
The Food and Drug Administration (FDA) approved three drugs for clinical use which are buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and by Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many medications considered essential to a functioning health care system.
The Global Market Is Analyzed in Depth in the Latest Study. Taking into account the current level of competition and its projected evolution over the next few years.
Rapidly increasing demands, a rise in industrialization, consumer awareness, growing sectors, and technical improvements are fueling the expansion of the global Medication-Assisted Treatment (MAT) market. Sales and revenue in this sector have increased at an exponential rate. The market's size and growth are both expected to increase thanks to the factors driving the market's expansion over the projected period.
Leading businesses in the Medication-Assisted Treatment (MAT) Industry are investing heavily in R&D in order to build a larger client base and expand their share of the market by reintroducing improved products to consumers. All of the companies' strategy, as well as their financial health, revenue, gross margin, and growth rate, are detailed in the study.
The Medication-Assisted Treatment (MAT) Market is Dominated by Firms Such as
- Indivior PLC,
- Orexo US Inc. (a subsidiary of Orexo AB),
- Recovery Centers of America,
- Alkermes.
- Sun Pharmaceutical Industries Ltd.,
- Purdue Pharma L.P.,
- Taj Pharmaceuticals Limited,
- Lannett,
- Hikma Pharmaceuticals PLC,
- Pfizer Inc.,
- Pinnacle Treatment Center,
- American Addiction Centers,
- Adamis Pharmaceuticals Corporation,
- Glenmark Pharmaceutical Inc.
- Viatris Inc.,
- Mallinckrodt,
- Alvogen,
- Accord Healthcare,
- VistaPharm, Inc.,
- Teva Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Amneal Pharmaceuticals LLC.
- Titan Pharmaceuticals
Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-medication-assisted-treatment-mat-market
Recent Development
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Opportunities for Key Players:
Moreover, the rise in research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
Strategic Initiative By Market Players
The demand for medication-assisted treatment has increased in the U.S. and Europe due to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
For instance,
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Key Market Segments Covered in Medication-Assisted Treatment (MAT) Industry Research
Type
- Medication
Products
- Buprenorphine and Naloxone
- Naltrexone
- Buprenorphine
- Methadone
- Naloxone
- Disulfiram
- Acamprosate
Drug Type
- Branded
Dosage Form
- Immediate Release
- Extended Release
Route of Administration
- Oral
- Parenteral
Population Type
- Teenage
- Adults
End User
- Rehabilitation Clinics
- Hospitals
- Speciality Centers
- Homecare
Distribution Channel
- Hospital Pharmacy
- Direct Tender
- Retail Pharmacy
- Online Pharmacy
Key Industry Drivers:
- he Rises In Incidence Of Alcohol Use Disorder and Opioid Use Disorders
Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, and alcohol addiction.
- Use Of Reimbursement For Medication-Assisted Treatment (MAT)
Reimbursement may be available for medication-assisted treatment even if the medication does not have a valid status.
Browse a Detailed Summary of the Research Report @
Medication-Assisted Treatment (MAT) Market Regional Analysis/Insights:
The countries covered in the medication-assisted (MAT) treatment market report are the U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland, and Rest of Europe., China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and the Rest of Middle East and Africa.
North America is expected to dominate the market due to a rise in the incidence of substance use disorders, ongoing clinical trials, and pharmaceutical companies.
It's in your best interest to take this report into consideration because:
- Strong and extensive research methods were used to construct this study. The thoroughness and precision of the market reports produced by Data Bridge Market Research have earned them a great reputation.
- A complete picture of the competitive scenario of Medication-Assisted Treatment (MAT) market is depicted by this report.
- The wide range of research on how these innovations may affect market expansion in the future.
- The report's findings are presented in an approachable format, with accompanying visuals (such as histograms, bar graphs, pie charts, etc.) that make the data readily digestible.
- The potential, threats, and difficulties in the Medication-Assisted Treatment (MAT) market, as well as the factors driving and restraining it, are discussed at length.
- It gives an all-encompassing evaluation of the anticipated conduct of the future market and the changing market condition.
- This study provides a number of strategic business approaches to assist you in making educated business decisions.
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Market Overview
- Global Medication-Assisted Treatment (MAT) Market, By Type
- Global Medication-Assisted Treatment (MAT) Market, By Products
- Global Medication-Assisted Treatment (MAT) Market, By Drug Type
- Global Medication-Assisted Treatment (MAT) Market, By Dosage Form
- Global Medication-Assisted Treatment (MAT) Market, By Route of Administration
- Global Medication-Assisted Treatment (MAT) Market, By Population Type
- Global Medication-Assisted Treatment (MAT) Market, By End User
- Global Medication-Assisted Treatment (MAT) Market, By Distribution Channel
- Global Medication-Assisted Treatment (MAT) Market, By Region
- Global Medication-Assisted Treatment (MAT) Market: Company Landscape
- SWOT Analyses
- Company Profile
- Questionnaires
- Related Reports
Get the Full Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-medication-assisted-treatment-mat-market
Explore More Reports:
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
